1-(3-Bromo-phenyl)-2,2,2-trifluoro-ethylamine hydrochloride, 95.0%, 5g

2-METHYL-5-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]-1,3,4-OXADIAZOLE, 95.0%, 1g

(R)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-bromophenyl)propanoic acid, 97%, 1g

1,2,2,6,6-Pentamethylpiperidine, 97.0%, 10g

INDOLINE-4-CARBONITRILE, 95.0%, 1g

4-(Trifluoromethylthio)benzoic acid, 97.0%, 5g

4-Bromo-2-isobutoxyaniline, 95%, 100mg

(2E)-3-(2,3-dimethoxyphenyl)-1-(2,4-dimethoxyphenyl)prop-2-en-1-one, 95.0%, 2g

6-Methoxy-2-methylpyridin-3-ol, 98%, 100mg

2-Amino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester, 98.0%, 500g

2-Fluoro-6-(trifluoromethyl)pyridine-3-carboxylic acid, 97%, 250mg

GC-Kapillarsäule ROTI®Cap-1701, L 30 m, Ø-Innen 0,32 mm, Filmd. 0,50 µm, 1 Stück

2,4-Dichloro-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidine, 95%, 250mg